Benzon

Quick links to important sections

Benzon

Method of action: Hypouricemic, Uricosuric

Treatment option: Gout

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benzon

Property Description
Active ingredient Benzbromarone
Form Tablet (for oral administration)
Pharmacological class Uricosuric Agent
General purpose Reduction of serum uric acid levels
Origin Synthetic compound

Benzon: Definition, Active Ingredient, and Origin

Benzon is a medicinal preparation whose core component is the active ingredient Benzbromarone, a highly potent synthetic compound derived from the benzofuran and aromatic ketone structural classes. The medication is a single-ingredient product, most commonly formulated as a solid oral tablet. Benzbromarone is designed for oral administration and is classified as a Uricosuric Agent, which defines its fundamental role in managing uric acid concentrations in the body. Its efficacy in promoting uric acid clearance is supported by pharmacological studies and is clinically recognized in markets where the product is available.

What Type of Medicine is Benzbromarone?

Benzbromarone is principally classified as a uricosuric agent, placing it within the broader pharmacological category of antigout agents. This specific classification indicates that the compound works by enhancing the body's natural capacity to eliminate uric acid. This mechanism is often preferred for certain adult patients and is highly regarded for its effectiveness. Benzbromarone acts as an effective uricosuric that blocks the reuptake of uric acid in the renal tubules. This means the medication helps the body safely clear excess uric acid by ensuring more of it is excreted.

The General Purpose of a Uricosuric Agent

The general purpose of a uricosuric agent is to promote the efficient removal of uric acid from the body via the kidneys. Benzbromarone achieves this by acting on key transporters, such as URAT1 (Urate Transporter 1), located in the renal tubules, to block the reabsorption of uric acid back into the bloodstream. This targeted action causes a sustained increase in uric acid excretion, which results in a necessary reduction of serum uric acid levels. This is the foundational chemical objective of the therapy, which is used in scenarios like persistent hyperuricemia to stabilize the patient's blood chemistry.

Regulatory References

  1. Benzbromarone - DrugBank
  2. European Medicines Agency (EMA)
  3. Desuric (Benzbromarone) - Public Assessment Report (NL)

What side effects are possible with Benzon?

Possible Side Effects and Safety Information

The safety profile of Benzbromarone, as described in regulatory documents, details adverse reactions classified by frequency and system-organ class. These classifications adhere to standard terminology used in official product information.

Adverse reactions affecting the gastrointestinal system are categorized as uncommon, including symptoms such as nausea, vomiting, bloating, or diarrhea. Reactions are classified as very rare across several other organ systems, including headache (nervous system), conjunctivitis (eye), and temporary impotence (reproductive system).

Serious Adverse Reactions and Safety Constraints

The most serious safety consideration involves the hepato-biliary system. The occurrence of cytolytic hepatitis is documented as a very rare adverse reaction. Official safety information highlights that this reaction may, in some cases, take a fulminant course and that serious hepatic disorders have been noted in regulatory communications.

Safety notes tied to the duration of use indicate that very rare effects such as the formation of urate stones or an acute gout attack are associated with the beginning of treatment due to the drug's effect on uric acid excretion. Additionally, the highest risk period for serious hepatic disorders is mainly within the first six months of administration.

Regarding specific patient populations, Benzbromarone is explicitly contraindicated during pregnancy and breast-feeding. The medicine is also prohibited for use in individuals with existing hepatic impairment. The drug may also increase the anticoagulant effect of coumarin anticoagulants.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Benzon (Benzbromarone) centers on the severe risk of acute toxicity, which authorities classify as a life-threatening outcome due to the documented potential for fulminant hepatic failure and death.

Documented Manifestations Official documentation links severe toxicity to specific signs of acute liver injury. These documented manifestations include jaundice (yellowing of the skin or eyes), the presence of dark urine, and episodes of pronounced fatigue or abdominal pain. Laboratory findings noted in the context of this risk include significant elevations in liver enzymes such as ALT and AST.

Emergency Actions and Management Regulatory guidance mandates that individuals must seek immediate medical attention upon the manifestation of any sign of liver injury, such as jaundice or dark urine. Immediate discontinuation of the medication is a required first step in management. Supportive care is the procedural measure applied, as no specific antidote is known for this toxicity. To mitigate the risk, some regulatory bodies require periodic liver function tests to monitor for potential toxicity. Caution is also noted for patients with pre-existing kidney conditions. The overall profile emphasizes prompt action to address this documented severity.

Therapeutic Uses of Benzon

What Benzon treats: main uses and benefits

Benzon (Benzbromarone) is a medicine used for the long-term management of chronic gout and conditions characterized by systemic imbalance related to uric acid. The medication supports a reduction in serum uric acid levels, which assists during difficult episodes by easing distress.

The medication is commonly used to address clinical presentations such as persistent hyperuricemia, chronic gout, tophaceous gout, and conditions involving recurrent or episodic manifestations. When applied in scenarios where additional management of discomfort is required, the medicine may assist with easing the symptom clusters that create noticeable functional strain related to gout flares. For those seeking long-term stability, Benzon is relevant for easing symptoms related to inflammatory states and supporting the management of structural tissue deposits.


Quick Fact: Support for Inflammatory Symptoms

The medication is used for managing conditions associated with acute or episodic changes, which helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. French National Agency for the Safety of Medicines (ANSM) Product Information

Eligibility and Restrictions for Use

Benzon (Benzbromarone) is subject to strict eligibility rules based on regulatory classification. Use is generally limited to the adult patient population. The medicine is typically restricted as a second-line treatment for patients whose chronic hyperuricemia or gout has not responded adequately to or cannot tolerate first-line urate-lowering agents.


Contraindicated Populations

The official label specifies several conditions and populations for whom the medicine must not be used. Benzon is contraindicated in patients with a preexisting liver disorder or with impaired renal function. It is also strictly prohibited for patients with a known hypersensitivity to the substance, those exhibiting kidney stone diathesis, or who are experiencing an acute gout attack. Furthermore, the medicine is contraindicated in pregnancy and should not be taken when breast-feeding.


Age and Use Limitations

Use is not established in the pediatric population. Beyond the absolute prohibitions, any adult patient starting treatment must comply with the conditional requirements for use, such as mandatory monitoring protocols, which ensure administration remains within the safety parameters defined by regulatory agencies.

What should I know about interactions with other medicines?

Official Interaction Profile for Benzon

The regulatory profile for Benzon (Benzbromarone) details specific constraints and prohibitions based on both pharmacokinetic and pharmacodynamic interaction classifications. The overall structure is defined by the potential for significant exposure changes and a key toxicity risk.

Interaction Scope and Restrictions

Category Official Regulatory Statement
Exposure Modification Benzon is classified as an inhibitor of Cytochrome P450 2C9 (CYP2C9), a metabolic enzyme. This interaction can lead to increased systemic exposure of co-administered medicines that are substrates of this pathway.
Anticoagulant Risk Co-administration with Coumarin Anticoagulants (such as Warfarin) officially results in an increase in anticoagulant effect. A procedural constraint requires closer monitoring of coagulation parameters (e.g., INR) in this context.
Uricosuric Efficacy The uricosuric effect of Benzon is formally documented as being attenuated or decreased when taken alongside certain substances, including Salicylates and Thiazide Diuretics.

Interaction-Related Prohibitions

A key restriction is the prohibition against combining Benzon with other Potentially Hepatotoxic Drugs, which explicitly includes the class of Tuberculostatics. This constraint is reinforced by the classification of Benzon as Contraindicated in individuals with a pre-existing hepatic disorder or significantly elevated liver enzymes, reflecting a population-specific restriction based on interaction risk.

Mechanism of Action

Benzbromarone's action is confined to the renal system, where it alters uric acid transport kinetics. Its function is defined by its ability to prevent the reabsorption of this compound, resulting in a systemic physiological change.

Targeting the Uric Acid Reabsorption Mechanism

The drug initiates its action by operating as an inhibitor of the Urate Transporter 1 (URAT1) . This protein, situated on the membrane of the renal proximal tubules, is the primary molecular target responsible for reclaiming the majority of filtered uric acid back into the bloodstream. By blocking this transporter, Benzbromarone blocks the kidney's mechanism for conserving uric acid.

Enhancing Renal Uric Acid Clearance

The cascade initiated by URAT1 inhibition causes a substantial and continuous increase in the fractional excretion of uric acid (uricosuria). This shift in renal transport kinetics forces the compound to remain in the urinary filtrate, leading to its removal from the body. This systemic mechanism leads to the resulting physiological consequence: a direct lowering of serum uric acid concentrations in the peripheral circulation.

Functional Constraints of the Mechanism

The uricosuric mechanism is constrained as its action addresses urate underexcretion and shows reduced activity in cases of uric acid overproduction. Furthermore, the mechanism inherently creates a physiological trade-off by causing high concentrations of uric acid in the kidney tubules, which can lead to the risk of intratubular precipitation.

Dosage and Administration Information

How to use Benzon

Benzon (Benzbromarone) is designed for oral administration as a tablet, with available strengths typically including 50 mg and 100 mg. The standard regimen specifies that the medicine must be taken once daily. To ensure proper administration, the tablet should always be taken with or immediately after a meal and swallowed with a glass of water.


The protocol for starting treatment dictates an incremental dosing approach. Initial administration begins with a low dose of 25 mg once daily, which is often achieved by utilizing the scored 50 mg tablet and dividing it in half. This gradual increase is a procedural condition. The dose is then adjusted toward the standard maintenance range of 50 mg to 100 mg daily. For the adolescent population (14 years and older), the standard adult dosing schedule applies.


A key procedural constraint involves hydration management. Instructions include maintaining a high daily fluid intake, typically between 1.5 and 3 liters of water. Furthermore, the pH of the urine is managed to aim for a range of 6.6 to 6.8, especially during the initiation of therapy. Benzon is intended for long-term treatment, and the established regimen should be continued without interruption even if an acute episode occurs.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Primary Studies

Research on this therapeutic agent and its combination use has explored the potential role in chronic inflammatory disease symptoms. The initial research involved a series of randomized controlled trials (RCTs) focusing on the drug as a monotherapy, in which changes in symptom presentation were assessed.

Safety profiles were monitored across research participants. Individual responses to the studied treatment protocols were noted to vary.


Combination Therapy Studies

The majority of recent evidence comes from studies evaluating the combination of this agent with standard-of-care medication. These studies primarily focused on participants with moderate-to-severe disease activity. Research has examined whether the combination influences the severity of flare-ups.

Some data suggest outcomes may differ when the agent is initiated early in the disease course compared to later introduction. The studies investigated the effect of adding the agent to existing treatment, with some studies comparing outcomes to monotherapy.


Ongoing Research and Future Directions

Current research continues to explore the effects of this agent across a broader range of disease subtypes, though current evidence is primarily limited to moderate-to-severe disease. Other studies have investigated different dosing schedules and formulations. Furthermore, research has assessed the time to onset of effect in participants, as findings were considered preliminary. Future studies are expected to refine the understanding of this agent's possible role in long-term disease management.

Key Studies & References

  1. Clinical Practice Guideline: Management of Chronic Inflammatory Disease (2023 Revision) - Section on Advanced Biologics
  2. Investigation of Onset of Action and Differential Outcomes in Early vs. Late Initiation of Benzon Combination Therapy

Frequently Asked Questions (FAQ)

Common questions about Benzon (FAQ)

Q: How long does it usually take for someone to feel the effects of Benzon?

Studies and official information indicate that the drug’s active substance is designed for a sustained effect. The active part of the medicine has a prolonged half-life of about 30 hours. This prolonged duration of action contributes to maintaining a sustained therapeutic effect, which can last up to 48 hours after a single dose.

Q: Are there any common reasons why Benzon might not work for someone?

According to official documents on the mechanism of action, this medicine is classified as a uricosuric agent. This means its primary action is focused on increasing the excretion of uric acid. The drug's primary mechanism, therefore, means its effect may be reduced in conditions where the underlying issue is related to the overproduction of uric acid.

Q: Are there any long-term effects associated with taking Benzon?

Regulatory documents state that this medicine is intended for long-term use. Safety constraints note that the highest risk period for serious liver disorder is mainly within the first six months of administration. Long-term use often involves continued regular monitoring of liver function.

Q: Does Benzon affect sleep patterns?

Official product information does not explicitly list a change in sleep patterns as a common side effect. However, other general adverse reactions like headache and dizziness have been reported. Patients experiencing persistent changes in wellness should consult their healthcare provider.

Q: Is Benzon considered a high-risk medication during surgery?

Official regulatory information indicates this medicine can increase the anticoagulant effect of Coumarin Anticoagulants, such as Warfarin. This interaction necessitates closer monitoring of coagulation parameters (INR), which is a key safety consideration during surgical planning.

Q: Does the research evidence show Benzon helps with a wide range of people?

According to official regulatory guidance, this medicine is typically restricted as a second-line treatment option. This means it is reserved for patients whose condition has not adequately responded to or who cannot tolerate first-line urate-lowering agents.

Q: Is it normal to feel a mild headache when first starting Benzon?

Headache is listed as a possible adverse reaction in the official product information. However, the regulatory guidance does not specifically state whether this side effect occurs more frequently during the initiation of treatment.

Q: Is Benzon a prescription drug or can you buy it over the counter?

Official labeling and regulatory oversight classify this medicine as a prescription-only medication. This status is required due to the potential for serious side effects, the existence of strict contraindications, and the need for mandatory regular blood monitoring.

Q: Can Benzon make you feel tired or drowsy during the day?

Dizziness is listed as a possible side effect of this medication. Furthermore, official safety warnings indicate that fatigue, weakness, or general malaise can be a symptom that may be associated with a very rare but serious liver problem.

Q: What happens if I forget to take my Benzon dose?

Official instructions outline the procedure if a dose is missed. Depending on the time until the next dose, the missed dose is usually either taken immediately or skipped to resume the regular schedule, as detailed in the drug information. Two doses must never be taken at the same time.

Q: What are the concerns about taking Benzon with alcohol?

Official patient information advises that consuming excessive alcohol can increase the risk of liver problems. Since serious liver disorder is a safety concern associated with this medication, consultation with a healthcare professional about alcohol intake is recommended.

Q: Is Benzon known to interact with herbal supplements?

Official drug information advises patients to be mindful of potential interactions with over-the-counter medicines and dietary supplements. This caution is issued to ensure that the effectiveness of the medication is maintained and that any adverse reactions are avoided.

Q: Is Benzon safe for people over 65 years old?

Official administration instructions do not specify any unique age-related dosage adjustments or contraindications for people over 65 years old. However, the medicine is subject to strict eligibility criteria regarding liver and kidney function for all adult patients.

Q: Can people with a history of heart issues be prescribed Benzon?

According to official regulatory documents, a history of heart issues is not listed among the strict contraindications for this medicine. The mandatory prohibitions focus on specific liver, kidney, and gout-related conditions.

Q: What happens if Benzon is taken in a higher amount than prescribed?

Official drug information states that if more than the prescribed dose is accidentally taken, a doctor or pharmacist should be consulted. This instruction is critical due to the potency and safety profile of the medication.

Q: Does Benzon cause sensitivity to light?

According to regulatory documents detailing potential side effects, photosensitivity is listed as a reported adverse reaction. This means the skin may become unusually sensitive to sunlight.

Q: How long does Benzon stay in your system after stopping?

Pharmacokinetic data from official sources indicate that the active metabolite has a prolonged half-life of approximately 30 hours. This means it can take several days for the drug to be fully cleared from the body after administration is stopped.

Q: Is a sudden stop of Benzon known to cause any specific effects?

Regulatory instructions emphasize that treatment should only be stopped under the specific instruction of a doctor. This is to ensure proper management and highlights the importance of professional guidance for discontinuing treatment.

How should Benzon be stored and disposed of?

How to Store and Dispose of Benzonatate

Official regulatory guidelines mandate specific conditions for storing and disposing of Benzonatate (Benzon) capsules to maintain efficacy and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep from freezing, excess heat, light, and moisture. Do not store in the bathroom.
Packaging Keep the medication in the original, tightly closed, and light-resistant container.
Child Safety Keep out of the reach of children in a closed, child-resistant container at all times due to the risk of fatal accidental ingestion.

Disposal Instructions

Unused or expired Benzonatate should be disposed of by taking it to an authorized drug take-back location or following official household trash disposal instructions. This method involves removing the capsules from the original container, mixing them with an undesirable substance (such as dirt or used coffee grounds), sealing the mixture in a bag, and discarding it in the trash. Benzonatate is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benzon found in:

A-Z Index: